Extra-Corporeal Membrane Oxygenation in Pregnancy
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(6), P. 1634 - 1634
Published: March 13, 2024
Extracorporeal
membrane
oxygenation
(ECMO)
is
a
cardiac
or
pulmonary
function
support
system
that
used
in
cases
of
refractory
organ
failure
addition
to
conventional
treatment.
Currently,
Level
I
evidence
not
yet
available,
which
reflects
improved
outcomes
with
ECMO
pregnant
women,
the
use
pregnancy
should
be
indicated
selected
and
only
specialized
centers.
We
searched
articles
most
important
scientific
databases
from
2009
until
31
December
2023
consulting
also
site
ClinicalTrials.com
find
out
about
studies
have
been
recently
conducted
are
currently
ongoing.
matched
combination
following
keywords:
“ECMO
pregnancy”,
“H1N1
“COVID-19
“ARDS
AND
(cardiac
arrest)”.
number
for
each
keyword
combination:
pregnancy”
(665
articles);
influenza
H1N1”
(384
“pregnancy
(1006
ARDS”
(2930
ARDS
(24
“[ECMO
arrest)]”
(74
articles).
After
careful
inspection,
43
papers
fitted
our
scope.
There
two
types
ECMO:
venous-venous
(VV-ECMO)
venous-arterial
(VA-ECMO).
The
first-one
necessary
cope
severe
hypoxia:
oxygen-depleted
blood
taken
venous
circulation,
oxygenated,
carbon
dioxide
removed
extracorporeal
circuit
returned
same
system.
VA-ECMO
type
mechanical
assistance
circulatory
allows
put
failing
at
rest
by
ensuring
adequate
systemic
de-oxygenation,
avoiding
multi-organ
failure.
main
indications
women
cardiogenic
shock,
acute
respiratory
distress
syndrome
(ARDS),
embolism,
eclampsia.
fetal
ECMO,
they
distress,
hypoxic-ischemic
encephalopathy
(HIE),
twin-to-twin
transfusion
(TTTS).
Until
now,
based
on
numerous
clinical
conducted,
has
shown
successful
therapeutic
strategy
where
medical
treatment
unsuccessful.
In
well-selected
patients,
it
appears
safe
associated
low
risk
maternal
complications.
aim
this
review
report
properties
(VV
VA)
its
women.
Language: Английский
Acute management of massive pulmonary embolism in pregnancy
Shahin Qadri,
No information about this author
Ashwini Bilagi,
No information about this author
Abha Sinha
No information about this author
et al.
Frontiers in Global Women s Health,
Journal Year:
2025,
Volume and Issue:
5
Published: Jan. 6, 2025
•Massive
pulmonary
embolism
(PE)
during
pregnancy
or
the
postpartum
period
is
a
rare
but
potentially
lethal
event.•Physiological
changes
in
coagulation
system
and
puerperium
would
lead
to
hypercoagulable
state.•Diagnosis
of
PE
remains
challenge
due
physiological
pregnancy.
There
are
no
validated
scoring
systems
for
assessing
pregnant/postpartum
women
with
suspected
PE.
Massive
should
be
all
cases
haemodynamic
instability
pregnancy.•The
Management
massive
timely
aggressive.
Thrombolysis
has
shown
associated
high
maternal
fetal
survival
(94%
88%).
But
other
therapeutic
options
such
as
(catheter
[or
surgical]
thrombectomy,
ECMO)
considered
period,
given
risk
major
bleeding
thrombolysis.•Thrombolysis
most-used
reasonably
successful
modality
treatment
avoided
it
can
cause
life-threatening
haemorrhage.
During
post-partum
thrombectomy
choice.
•To
understand
pathophysiology
PE.•To
appreciate
their
pros
cons.•To
need
further
work
this
area
especially
creating
algorithm
diagnosing
period.
Language: Английский
Extracorporeal Membrane Oxygenation in Pregnant and Postpartum Women With Critical Coronavirus Disease 2019 (COVID-19) Acute Respiratory Distress Syndrome
Amir A. Shamshirsaz,
No information about this author
John J. Byrne,
No information about this author
Patrick S. Ramsey
No information about this author
et al.
Obstetrics and Gynecology,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Nov. 9, 2023
OBJECTIVE:
To
estimate
the
maternal
survival
and
live-birth
rates
in
pregnant
women
with
acute
respiratory
distress
syndrome
(ARDS)
secondary
to
critical
coronavirus
disease
2019
(COVID-19)
who
are
treated
extracorporeal
membrane
oxygenation
(ECMO)
by
performing
a
systematic
review
meta-analysis.
DATA
SOURCES:
From
database
inception
through
August
2023,
we
explored
MEDLINE,
Web
of
Science,
EMBASE,
CINAHL,
ClinicalTrials.gov,
Cochrane
Central
Register
Controlled
Trials.
Studies
reporting
COVID-19
undergoing
ECMO
were
included.
METHODS
OF
STUDY
SELECTION:
Two
reviewers
separately
ascertained
studies,
obtained
data,
evaluated
study
quality.
Summary
estimates
measured,
95%
CIs
calculated.
TABULATION,
INTEGRATION,
AND
RESULTS:
Nine
retrospective
case
series
12
cohort
studies
identified
386
underwent
ECMO.
that
from
January
2020
October
2022.
Four
United
States;
three
Turkey;
two
France;
Israel;
one
each
was
Columbia,
Germany,
Italy,
Kuwait,
Poland,
Republic
Srpska,
Arab
Emirates,
Kingdom,
consortium
Belgium,
France,
Switzerland,
an
international
registry.
The
pooled
rate
among
patients
initiated
on
75.6%
(95%
CI,
66.0–84.1%,
I
2
=72%).
83.7%
76.8-89.6%,
153
neonates,
=11%).
When
examined
separately,
results
similar.
CONCLUSION:
Among
attributable
managed
ECMO,
high.
SYSTEMATIC
REVIEW
REGISTRATION:
PROSPERO,
CRD42023442800.
Language: Английский
Use of Extracorporeal Membrane Oxygenation for Patients with Coronavirus Disease 2019 Infection
Advances in Surgery,
Journal Year:
2024,
Volume and Issue:
58(1), P. 249 - 273
Published: June 29, 2024
Language: Английский
Pregnancy and COVID-19: Comparing ICU Outcomes for Pregnant and Nonpregnant Women
Viruses,
Journal Year:
2024,
Volume and Issue:
17(1), P. 51 - 51
Published: Dec. 31, 2024
Background:
This
study
compares
organ
dysfunction,
treatment
strategies,
and
unfavorable
outcome
rates
between
pregnant
nonpregnant
women
admitted
to
the
ICU
with
severe
COVID-19,
highlighting
increased
susceptibility
of
respiratory
infections
due
physiological
changes.
Methods:
A
retrospective,
age-matched
was
conducted
at
a
referral
center
specializing
in
critical
care
for
women.
Data
from
14
pregnant/postpartum
11
were
analyzed
admission
on
days
3,
5,
7.
Results:
Acute
distress
syndrome
diagnosed
100%
group
64%
(p
=
0.026).
Inflammatory
parameters
similar
groups,
except
lower
ferritin
levels
compared
(120
vs.
568
µg/L
90
616
day
3).
Creatinine,
lactate,
lactate
dehydrogenase
significantly
group.
reduction
SOFA
score
observed
over
time
(from
7.0
4.0
points,
p
0.009),
while
no
change
noticed
3.0
2.5
0.181).
Unfavorable
similar,
two
patients
each
succumbing
disease
0.604).
Conclusions:
The
findings
suggest
that
pregnancy
does
not
increase
risk
outcomes
among
COVID-19
receiving
treatment.
However,
additional
studies
larger
sample
sizes
are
needed
validate
these
observations.
Language: Английский